bcl-2 proto-oncogene, apoptosis and oncogenesis: An overview

International Journal of Oncology

Volumn 9, Issue 3, 1996, Pages 563-566

  Kandouz, Mustapha ^a   Gompel, Anne ^a   Therwath, Amu ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

apoptosis; bcl 2 proto oncogene

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIVISION; DIAGNOSIS; GENE EXPRESSION REGULATION; GENE STRUCTURE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0029815350     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Kerr JFR, Wyllie AH and Currie A: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
2. Wyllie AH, Kerr JFR and Currie AR: Cell death: the significance of apoptosis. Intern Rev Cytol 68: 251-306, 1980.
3. Ellis RE, Yuan J and Horvitz HR: Mechanisms and functions of cell death. Annu Rev Cell Biol 7: 663-698, 1991.
4. Schwartzman RA and Cidlowski JA: Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrine Rev 14: 133-150, 1993.
5. Wyllie AH, Morris RG, Smith AL and Dunlop D: Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67-77, 1984.
6. Raff M: Social controls on cell survival and cell death. Nature 356: 397-400, 1992.
7. + thymocytes by flow cytometry. J Immunol Methods 37: 79-87, 1991.
8. Cohen JJ and Duke RC: Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 132: 38-42, 1984.
9. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild type p53. Science 249: 912-915, 1990.
10. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, et al: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781, 1990.
11. Williams GT, Smith CA, Spooncer E, Dexter TM and Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343: 76-79, 1990.
12. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E and Spandidos D: Rodent fibroblast tumours expressing myc and ras genes. Growth, metastasis and endogenous oncogene expression. Br J Cancer 56: 251-259, 1987.
13. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brook M, Waters CM, Penn LZ and Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-129, 1992.
14. Kyprianou N, Alexander RB and Isaacs JT: Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst 83: 346-350, 1991.
15. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase M, Seto Y and Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
16. Miura M, Zhu H, Rotella R, Hartwieg EA and Yuan J: Induction of apoptosis in fibroblasts by II-1ß-Converting Enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75: 653-660, 1993.
17. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jack S: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
18. Ellis RE, Yuan J and Horvitz HR: Mechanisms and functions of cell death. Annu Rev Cell Biol 7: 663-698, 1991.
19. Vaux DL, Cory S and Adams JM: bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
20. Hockenbery DM, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: bcl-2 is an inner mitocnondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
21. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP and Korsmeyer SJ: Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144: 3602-3610, 1990.
22. Deng G and Podack ER: Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA 90: 2189-2193, 1993.
23. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP and Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57: 79-88, 1989.
24. McDonnell TJ: The bcl-2-immunoglobulin transgenic mouse: a model of the t(14;18) translocation in human follicular lymphoma. Transgene 1: 47-52, 1993.
25. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P and Korsmeyer SJ: Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J 7: 123-131, 1988.
26. Tsujimoto Y, Ikegaki N and Croce CM: Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 2: 3-7, 1987.
27. Chen-Levy S and Cleary ML: Membrane topology of the bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 265: 4929-4933, 1990.
28. Chen-Levy Z, Nourse J and Cleary ML: The bcl-2 candidate proto-oncogene product is a 24 kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9: 701-710, 1989.
29. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY and Greaves MF: Ultrastructural localization of Bcl-2 protein. J Histochem Cytochem 40: 1819-1825, 1992.
30. Nakai M, Takeda A, Cleary ML and Endo T: The Bcl-2 protein is inserted into the outer membrane but not the inner membrane of rat liver mitochondria in vitro. Biochem Biophys Res Commun 196: 233-239, 1993.
31. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the Bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701-4714, 1993.
32. Tanaka S, Saito K and Reed JC: Structure-function analysis of the Bcl-2 oncoprotein. J Biol Chem 268: 10920-10926, 1993.
33. Akao Y, Otsuki Y, Kataoka S, Ito Y and Tsujimoto Y: Multiple subcellular localization of Bcl-2: detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membranes. Cancer Res 54: 2468-2471, 1994.
34. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL and Korsmeyer S: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251, 1993.
35. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Örd T and Bredesen DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262: 1274-1277, 1993.
36. 2+ fluxes. Proc Natl Acad Sci USA 91: 6569-6573, 1994.
37. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
38. Fernandez-Sarabia MJ and Bischoff JR: Bcl-2 associates with the Ras-related protein R-Ras p23. Nature 366: 274-275, 1993.
39. Wang H-G, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L III, Troppmair J, Rapp UR and Reed JC: Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9: 2751-2756, 1994.
40. Haldar S, Jena N and Croce C: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
41. Fukuhara S, Rowley JD, Varrakojis D and Golomb HM: Chromosome abnormalities in poorly differenciated lymphocytic lymphoma. Cancer Res 39: 3119-3128, 1979.
42. Tsujimoto Y, Cossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985.
43. H on chromosome 14 and near a transcripional unit on 18. Cell 41: 899-906, 1985.
44. Cleary ML and Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82: 7439-7443, 1985.
45. Cleary ML, Smith SD and Sklar J: Cloning and structural analysis of cDNAs for bcl-1 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47: 19-28, 1986.
46. Tanaka S, Louie DC, Kant JA and Reed JC: Frequent incidence of somatic mutations in translocated bcl-1 oncogene of Non-Hodgkin's lymphomas. Blood 79: 229-237, 1992.
47. Reed J, Tsujimoto Y, Epstein S, Cuddy M, Slabiak T, Nowell P and Croce C: Regulation of bcl-1 gene expression in lymphoid cell lines containing t(14;18) or normal #18 chromosomes. Oncogene Res 4: 271-282, 1989.
48. Hanada M, Delia D, Aiello A, Stadtmauer E and Reed J: bcl-2 gene hypomethylation and high-level expression in B-cell chronic leukemia. Blood 82: 1820-1828, 1993.
49. Hockenbery DM, Zutter M, Hickey W, Nahm M and Korsmeyer S: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.
50. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M and Campbell ML: Expression of the protooncogene bcl-1 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
51. Le Brun DP, Warnke RA and Cleary ML: Expression of Bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142: 743-753, 1993.
52. Lu QL, Poulsom R, Wong L and Hanby AM: Bcl-2 expression in adult and embryonic non haematopoietic tissue. J Pathol 169: 431-437, 1993.
53. Colombel M, Symmans F, O'Toole KM, Chopin D, Benson M, OIsson CA, Korsmeyer S and Buttyan R: Detection of apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
54. Hague A, Moorghen M, Hicks D, Chapman M and Paraskeva C: Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9: 3367-3370, 1994.
55. Leek RD, Kaklamanis L, Oezzela F, Gatter KC and Harris AL: Bcl-2 in normal human breast and carcinoma, association with ER positive EGFR negative tumours and in situ cancer. Br J Cancer 69: 135-139,1994.
56. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Mcd 329: 690-694,1993.
57. lkegaki N, Katsumata M, Minna J and Tsujimoto Y: Expression of Bcl-2 in small cell lung carcinoma cells. Cancer Res 54: 6-8, 1994.
58. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C and Pleasure D: Differential expression of bcl-2 protooncogcne in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51: 6529-6538,1991.
59. Sabourin JC, Martin A, Baruch J, True JB, Compel A and Poitout P: Bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59: 1-6, 1994.
60. Compel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y and Poitout P: Bcl-2 expression in normal endo-metrium during the menstrual cycle. Am J Pathol 144: 1195-1201, 1994.
61. Teixeira C, Reed JC and Pratt Mac: Estrogen promotes chemotherapcutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
62. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S and Gelmann EP: Androgens induce resistance to Z>c/-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55: 735-738,1995.
63. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS and Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445,1995.
64. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW and Vogelstein B: Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 54: 3714-3717,1994.
65. Nunez G and Clarke M: The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 4: 399-403,1994.
66. Bissonnette RP, Echeverri F, Mahboubi A and Green DR: Apoptotic cell death induced by c-Myc is inhibited by Bcl-2. Nature 359: 552-554, 1992.
67. Fanidi A, Harrington EA and Evan GI: Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556,1992.
68. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097,1994.
69. Miyashita T, Harigai M, Hanada M and Reed JC: Identification of a p53-dependent negative element in the bcl-2 gene. Cancer Res 54: 3131-3135,1994.
70. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E and Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65: 1107-1115,1994.
71. Henderson S, Huen D, Rowe M, Dawson C, Johnson G and Rickinson A: Epstein-Barr virus-coded BHRFl protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sei USA 90: 8479-8483, 1993.
72. Hickish T, Robertson D, Clarke P, Hill M, Di Stefano F, Clarke C and Cunningham D: Ultrastructural localization of BHRFl: An Epstein-Barr virus gene product which has homology with Bcl-2. Cancer Res 54: 2808-2811,V1994.
73. Zauli G, Gibellini D, Milani D, Mazzoni M, Borgatti P, La Plaça M and Capitani S: Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res 53: 4481-4485, 1993.